Noooo... it's not. You are stupid as an investor.
UCLA researchers, particularly through the Jonsson Comprehensive Cancer Center, have developed and are testing several dendritic cell (DC)-based vaccines beyond DCVax-L (a personalized tumor lysate-loaded DC vaccine for glioblastoma pioneered by Dr. Linda Liau). These focus on various cancers, often combining DCs with genetic modifications, adjuvants, or checkpoint inhibitors to enhance immune responses.
Personalized DC vaccine + poly-ICLC
Malignant glioma (aggressive brain tumors)
Patient-derived DCs loaded with tumor antigens, paired with poly-ICLC (a TLR3 agonist) to activate DCs and increase T-cell frequency/infiltration while reducing tumor immunosuppression.
Phase I/II trial results published (2024); showed improved immune response vs. vaccine alone; led by Dr. Robert Prins
UCLA maintains several specialized cleanroom facilities tailored for advanced research and manufacturing, particularly in nanofabrication, biotechnology, and cell/gene therapy production. These are essential for sterile environments required in developing and producing therapies like dendritic cell (DC) vaccines, where contamination must be minimized during cell manipulation and processing.
Market Data 
Markets 
AI
